Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LONDON, December 12 /PRNewswire/ --

- With Photo

The personalised dummy from http://www.MyDummy.co.uk is featured in the recent edition of People Magazine in the mouth of none other than Heidi Klum and Seal's son Henry Samuel. But this is only one of the many success stories for the just 2 1/2-year-old invention.

In September, Hollywood star Trista from the TV series The Bachelor and The Bachelorette, showed off the MyDummy in a big report in US Weekly magazine. Also, at last year's Awards ceremony, the MyDummy was chosen to be part of the exclusive VIP gift bags given to the award-nominated actors and actresses. Among the lucky recipients were the stars from Desperate Housewives and Kiefer Sutherland from 24 Hours.

MOUNTAIN VIEW, California, December 12 /PRNewswire/ --

Bytemobile, Inc., the global leader in mobile internet solutions for network operators, today announced the general availability of its Unison(TM) Advertising Module (UAM), which enables operators to serve targeted ads in off-portal web pages on virtually all mobile devices. As a result, carriers can quickly create new ad revenue streams to complement data revenues and subsidize the cost of data delivery.

LONDON, December 12 /PRNewswire/ -- Misys plc (FTSE: MSY.L), the global application software and services company, today announces that Banco Itau has migrated Banespa's customers with Misys Equation in its Japanese operations. Banco Itau also use Misys' core banking solution, Midas, for its American and offshore operations.

Following the acquisition of the customers of Banespa (Banco do Estado de Sao Paulo) Tokyo Branch at the end of 2006, Banco Itau immediately needed to manage the increase in the volume of deposits and remittances the additional operations brought in Japan. All Banespa's customer records and information from the Tokyo operations were transferred across to Misys Equation.

AMSTERDAM, the Netherlands, December 12 /PRNewswire/ --

- Forty-five Prestigious Journals to be Launched on ScienceDirect in Response to Customer Demand

Elsevier, a leading publisher of scientific, technical and medical (STM) information, today announced that 45 French-language medical journals from Elsevier Masson will be available on ScienceDirect beginning January 3, 2008.

ZUG, Switzerland, December 12 /PRNewswire/ -- Swiss Hawk AG's portfolio company Vitaboost International BV launches its new website with online shop today. The new online shop enables customers from all over Europe to order Vitaboost products online. In addition, Vitaboost products will be available in stores from Friday 14th December. The first Vitaboost product is the "Vitaboost Activator", a healthy energy drink product for everyday use with a base of orange, grape and lime juice enriched with Ginkgo Biloba, Taurin, Ginseng, Vitamin B Complex, Vitamin C, Caffeine, Schisandra and Guarana. Check out http://www.vitaboost.com for more information.

About Vitaboost International BV

FRIMLEY, England, December 12 /PRNewswire/ --

- Approximately 78% of Beta-thalassaemia Patients had Decreases in Cardiac Iron and 90% had Decreases in Liver Iron After Six Months, Interim Data Show(1)

- Study in Sickle Cell Disease (SCD) Patients With Iron Overload Showed Continued Safety and Efficacy Over Two Years(2)

- Safety and Efficacy Demonstrated in Lower-Risk Myelodysplastic Syndromes (MDS) Patients(3)